1. Introduction
===============

1.1. The proof-of-concept: SARS-CoV and its proteome
----------------------------------------------------

Severe Acute Respiratory Syndrome (SARS) is the first severe and readily transmissible new disease to emerge in the 21st century. Although much about SARS remains poorly understood, it is clear that this disease has major implications, both for public health and the global economy. SARS emerged amongst the Chinese population in mid November 2002, but did not leave Guangdong Province until mid February 2003, when an infected individual brought the virus to a hotel in Hong Kong. From there, hotel guests rapidly disseminated the disease to distant places, such as Singapore, Vietnam and Canada. On August 7, 2003, 8422 cases were confirmed worldwide with overall case fatalities estimated at 14--15%; in persons over 50, the fatality exceeded 50%. SARS dramatically demonstrates the global havoc wreaked by a newly emerging infectious disease.

The World Health Organization coordinated an international investigation through its Global Outbreak Alert and Response Network (<http://www.who.int/csr/outbreaknetwork/en/>) and worked closely with health authorities in the affected countries to provide epidemiological, clinical and logistical support. Interestingly, the SARS outbreak came at a critical point when the scientific community was actively launching structural genomics projects ([@bib8]). The large size of the SARS-CoV RNA genome (∼30 kb) justified a structural genomic approach in itself. A number of research groups around the world responded immediately to the challenge of SARS being the first pandemic of the new millennium. Four months after the outbreak, the virus was identified as a new class of coronavirus ([@bib13]), 2 weeks later the genome sequencing was completed ([@bib10], [@bib17], [@bib28]). The first structural model of a SARS-CoV protein was reported within another month ([@bib2]) and the initial description of the proteome was reported a few months later ([@bib21], [@bib25]). Since then, a number of groups around the world have worked towards the complete structural description of the proteome and all related functions ([@bib1], [@bib4], [@bib5], [@bib6], [@bib7], [@bib9], [@bib11], [@bib12], [@bib14], [@bib15], [@bib16], [@bib18], [@bib19], [@bib20], [@bib24], [@bib23], [@bib27]). While a number of important contributions were made by individual groups, a very systematic approach was taken by the European, US and Asian structural proteomics teams. [Fig. 1](#fig1){ref-type="fig"} shows the current state of the structural biology of SARS-CoV related proteins.Fig. 1A schematic depicting the progress made in structural characterization of the SARS-CoV proteome. The top two panels show the mature proteins that emerge from the replicase polyprotein while the bottom panel shows the ORFs for structural and accessory proteins. The individual domains of nsp3 derived by *in silico* analysis are shown in the inset. Those proteins whose structures have been described in the literature are shown as ribbon diagrams that are color coded from the N- (red) to the C-terminus (blue).

The coordination amongst the principal investigators of the research teams involved has led to efficient communication of progress and exchange of reagents. Updates on progress and joint publication strategies have effectively leveraged the competencies in each of the teams. In the US, the participation in the systematic investigation of the structures of all proteins in the proteome was primarily through the NIH NIAID Proteomics Resource Center for Biodefense and Emerging Infectious Diseases program and its support of the center for Functional and Structural Proteomics of SARS-CoV (FSPS) related proteins (<http://visp.scripps.edu/sites/sars>; [http://www.proteomicsresource.org](http://www.proteomicsresource.org/)). The aim was to characterize the complete proteome of SARS-CoV related proteins both structurally and functionally to provide initial validation to targets for drug discovery and vaccine development. This systematic approach is providing the coronavirus community with structural insight at an unprecedented rate leading constantly to new scientific findings.

Critical to this success in structural elucidation was the worldwide participation of exceptional competencies and effective collaboration amongst these experts in the field. In Europe, the research groups participating through Structural Proteomics In Europe (SPINE) (<http://www.spineurope.org/>) and VIZIER (<http://www.vizier-europe.org/>) included Professors Canard, Hilgenfeld, and Stuart. SPINE was one of the earliest funded integrated research projects (October 2003--2006) bringing together top European structural biology institutions in an unprecedented collaborative effort to develop new methods and technologies for high-throughput structural biology. SPINE was funded within Framework V of the European Commission and coordinated by Professor Dave Stuart of the Division of Structural Biology, University of Oxford. The project ran for 3 years from October 1, 2003 and involved more than 20 partners in 11 European countries working together to build a standard pipeline for identifying protein structures important for new drug discovery. VIZIER was funded though Framework VI of the European Commission and focuses on viral enzymes involved in replication. In addition, the European Commission supported SARS-CoV research through several Specific Targeted Research Projects. Two of these also made important contributions to SARS-CoV structural genomics: SEPSDA ([http://www.sepsda.biochem.uni-luebeck.de](http://www.sepsda.biochem.uni-luebeck.de/)), which was coordinated by Professor Rolf Hilgenfeld at the University of Lübeck, and SARS-DTV ([http://www.sars-dtv.nl](http://www.sars-dtv.nl/)), coordinated by Professor Willy Spaan and Eric Snijder at Leiden University MedicalCenter. In the US, the FSPS program of the NIAID Proteomics Resource Center involves the laboratories of Professors Kuhn, Buchmeier, Stevens, Wüthrich, and Wilson.

This consortia network is then expanded with individual research teams including Professor Zihe Rao and colleagues of Tsinghua University in Beijing and Professor Tai-huang Huang and colleagues of Taiwan\'s Academica Sinica and Professor Andrew Mesecar of the University of Chicago, USA and Professor Richard Kuhn of Purdue University, USA.

The coordination amongst these groups has formal and informal aspects. For example, the structure and function of the PLP Protease was jointly determined by the FSPS team and the Mesecar group combining expertise in nanovolume crystallization and protease enzymology. Publications on the non-structural protein 10 were coordinated amongst the Rao and FSPS teams and following the initial work on nsp15 by the VIZIER team, the reagents were exchanged with the FSPS and Rao teams to allow the structural elucidation and interpretation in a different space group and functional state. While the senior investigators frequently converse via electronic mail and at meetings, the students in the labs are also frequently exchanging information and working jointly on projects. Two recent graduates from the Rao laboratory started in the Kuhn laboratory at The Scripps Research Institute and lab members from the Mesecar lab just presented their recent findings at the bi-weekly FSPS meeting.

Formal meetings on the topic of emerging and re-emerging infectious diseases such as the workshop on Discovery of Antiviral compounds in Lübeck, 2006 are used, where members from EU, US and China present and share their progress. The annual meeting of the American Society of Microbiology has also served as a forum for exchange of both, published and unpublished data. As a result of the efforts by the NIH NIAID, reagents and procedures are being deposited to and made available by the BEI Resources \[[http://www.beiresources.org](http://www.beiresources.org/)\].

1.2. Technologies
-----------------

The last decade has seen a rapid development of miniaturized, automated and integrated methods and instrumentation development for structural biology ([@bib8]). While initially only applied to simple prokaryotic organisms ([@bib8]), it is now clear that these approaches are critical to the rapid understanding of complete viral organisms at the structural and functional level in support of developing means of therapeutic intervention. Clearly, these methods are being pushed to their limits and continued development is required that will ultimately enable individual laboratories and large international teams to tackle viral proteomes of both, emerging and re-emerging diseases. Many of the participating research groups are constantly developing, improving and sharing new technologies ([@bib3], [@bib22]) to more reliably and faster clone, express, purify, crystallize, and functionally characterize viral proteins. A significant advancement of what was accomplished over the past 2 years through the biology-guided approach, which demonstrated that many of these methods and instrumentation had reached a level of maturity so that they could be applied rapidly to new problems. Intellectual drivers for these experiments have, in many cases, been the virologists. This development will likely prevail over the coming decade as more and more of the traditionally specialized resource intensive experiments such as mammalian or baculoviral expression systems, automated high-throughput crystallization and the use of international and local synchrotron sources have been streamlined and implemented for widespread laboratory use. Examples like miniaturized and automated crystallization and imaging systems as well as next generation crystallization geometries have demonstrated how new technologies can accelerate discovery on challenging targets. The next wave of these technology developments is now being driven by new roadblocks in the quest for high content structural biology on challenging targets such as viral proteins and their host partners.

2. Conclusion---future prospect
===============================

Pathogenic viruses do not know any frontiers. Perhaps the greatest boost to viral structural genomics was the availability of the SARS-CoV sequence on the internet, as well as the openness of the small but dynamic coronavirus research world. Strains, sequences, clones, databases and all sorts of viral resources should become more easily available to appropriate labs, and large-scale efforts such as those ongoing in VIZIER and FSPS should be coordinated and bridged to other groups worldwide. (Investigators interested in joining this collaborative network are invited to contact the authors.) Structural proteomics has the great advantage of delivering atomic coordinates that can be quickly disseminated and not only used to considerably speed-up crystallographic problems but also promote cooperation. Given the importance of these pathogens and the possible worldwide impact of an outbreak, it is critical that the scientific community takes responsibility for addressing the needs for identifying and validating targets of therapeutic intervention. In this respect, the short response time of such big consortia has been truly remarkable in providing, for example, key structural data on SARS-CoV enzymes a prerequisite for expediting state-of-the-art drug design. This has been clearly demonstrated by the complementary work of the Canard, Rao and Kuhn labs on nsp15, a critical coronavirus endoribonuclease ([@bib6], [@bib16], [@bib26]).

Programs like VIZIER and FSPS are laying the foundation for any emerging virus and are delivering first line research products for the discovery of vaccines and therapeutics. The availability of reagents and methods for the production of the viral proteins, the high-resolution structural information, the functional and high-throughput assays, and small molecule tool compounds provide the starting point for drug discovery efforts in both, academic and pharmaceutical settings.
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